CoChat
Sign Up
Cited by 53Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: A post-hoc analysis of the BIGPRO1 trial

Fontbonne, A., Diouf, I., Baccara-Dinet, M., Eschwege, E., Charles, M.-A.·2009·Diabetes & Metabolism
DOI 10.1016/j.diabet.2009.03.005
Open this paper in CoChat — free account

Abstract

Aim Metformin has recently been considered as a possible pharmacological complement to lifestyle measures for preventing type 2 diabetes in high-risk subjects. However, little is known of its effects on metabolic and cardiovascular risk factors in non-diabetic subjects.Methods The BIGPRO1 trial was a 1-year multicentre, randomized, double-blind, controlled clinical trial of metformin versus placebo, carried out in the early 1990s, in 457 upper-body obese non-diabetic subjects with no cardiovascular diseases or contraindications to metformin. We compared the changes (1-year minus baseline) in cardiometabolic risk factors between treatment groups in two subsets of trial subjects: those with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (n=101); and those who fulfilled the inclusion criteria of the Diabetes Prevention Program (DPP) (n=51). Comparisons were adjusted for age and gender.Results In the IFG/IGT subset, significant differences in 1-year changes were observed for systolic blood pressure, which decreased markedly more in the metformin group than in the placebo group (P<0.003), and for fasting plasma glucose, and total and LDL cholesterol, which decreased slightly in the metformin group, but increased in the placebo group (P<0.04). Similar results were observed in the subset with DPP criteria. Also, there were no significant differences in 1-year changes for weight, waist-to-hip ratio, 2-h post-load blood glucose, fasting and 2-h post-load insulin, HDL cholesterol, triglycerides and fibrinolytic markers between the two treatment groups.Conclusion In subjects at high risk of developing diabetes, the use of metformin showed beneficial and no untoward effects on cardiometabolic risk factors.

Integrity signals

Registry

Crossref · 10.1016/j.diabet.2009.03.005

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the BIGPRO1 trial in upper-body obese non-diabetic subjects with no cardiovascular diseases or contraindications to metformin, blood pressure decreased significantly more in the IFG/IGT subgroup treated with metformin compared to placebo.

    “In the BIGPRO1 trial carried out in upper-body obese non-diabetic subjects with no cardiovascular diseases or contraindications to metformin, blood pressure decreased significantly more in the IFG/IGT subgroup treated with metformin compared to the placebo group (p < 0.03) [111].”

    From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [111]

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Fontbonne, A., Diouf, I., Baccara-Dinet, M., Eschwege, E., & Charles, M.-A.
Affiliations
  • Institut Agro Montpellier (FR)
  • Inserm (FR)
Corresponding author
Fontbonne, A.
ORCID
Venue
Diabetes & Metabolism
Publisher
Elsevier BV
Published
2009-11
Volume
35
Issue
5
Pages
385-391
ISSN
1262-3636 (ISSN-L)
DOI
10.1016/j.diabet.2009.03.005
OpenAlex
W2002413871
Cited by
53
References
41
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 2 · 2014: 5 · 2013: 7 · 2012: 4
FWCI
2.42
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Diabetes & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
Institute Pasteur De Lille
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
metformin, upper body obesity, impaired fasting glucose, impaired glucose tolerance, cardiometabolic risk factors, type 2 diabetes prevention, systolic blood pressure, LDL cholesterol, fasting blood glucose, insulin, lifestyle intervention
MeSH terms
Adult, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Risk Factors, Glucose Intolerance, Metabolic Syndrome, Obesity, Abdominal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review